Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess the efficacy and safety of 32 mg naltrexone sustained-release (SR)/360 mg bupropion SR (NB) in overweight/obese individuals with type 2 diabetes with or without background oral antidiabetes drugs. RESEARCH DESIGN AND METHODS: This was a 56-week, double-blind, placebo-controlled study in which 505 patients received standardized lifestyle intervention and were randomized 2:1 to NB or placebo. Coprimary end points were percent weight change and achievement of ≥5% weight loss. Secondary end points included achievement of HbA1c <7% (53 mmol/mol), achievement of weight loss ≥10%, and change in HbA1c, waist circumference, fasting blood glucose, and lipids. RESULTS: In the modified intent-to-treat population (54% female, 80% Caucasian, and mean age 54 years, weight 106 kg, BMI 37 kg/m2, and HbA1c 8.0% [64 mmol/mol]), NB resulted in significantly greater weight reduction (−5.0 vs. −1.8%; P < 0.001) and proportion of patients achieving ≥5% weight loss (44.5 vs. 18.9%, P < 0.001) compared with placebo. NB also resulted in significantly greater HbA1c reduction (−0.6 vs. −0.1% [6.6 vs. 1.1 mmol/mol]; P < 0.001), percent of patients achieving HbA1c <7% (53 mmol/mol) (44.1 vs. 26.3%; P < 0.001), and improvement in triglycerides and HDL cholesterol compared with placebo. NB was associated with higher incidence of nausea (42.3 vs. 7.1%), constipation (17.7 vs. 7.1%), and vomiting (18.3 vs. 3.6%). No difference was observed between groups in the incidence of depression, suicidal ideation, or hypoglycemia. CONCLUSIONS: NB therapy in overweight/obese patients with type 2 diabetes induced weight loss, which was associated with improvements in glycemic control and select cardiovascular risk factors and was generally well tolerated with a safety profile similar to that in patients without diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Even so, in subanalyses, persons losing more than 10% of weight at 1 year experienced a 21% reduction in the composite CVD outcome.734”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [734]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Similar attenuation in weight loss in patients with vs without type 2 diabetes has been observed with other AOM, including orlistat,(44) naltrexone-bupropion,(45) and liraglutide 3.0 mg,(46) as well as with some behavioral interventions.(47, 48)”
From Semaglutide for the treatment of obesity (2023) · cites this paper as [45]
The cited source says what the claim attributes to it.
In the citing paper
“In COR-Diabetes, naltrexone/bupropion yielded − 5% weight loss and − 0.6% HbA1c reductions [35].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [35]
In the citing paper
“Naltrexone plus bupropion extended-release reduces weight on average by ≈7% (≈5% placebo-subtracted) [51][52][53][54] and also more than either agent administered alone.55”
From Approach to Obesity Treatment in Primary Care: A Review (2024) · cites this paper as [52]
In the citing paper
“Other AOMs have yielded comparably smaller weight losses in patients with versus without type 2 diabetes [58].”
From The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities (2023) · cites this paper as [58]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Prevalence of Obesity and Trends in the Distribution of Body Mass Index Among US Adults, 1999-2010
Flegal, K. M., Carroll, M. D., Kit, B. K., & Ogden, C. L. (2012) · JAMA · doi:10.1001/jama.2012.39 · Cited by 5,385
Abdominal obesity and metabolic syndrome
Després, J.-P., & Lemieux, I. (2006) · Nature · doi:10.1038/nature05488 · Cited by 4,354
Christiane, Druml, Wolzt, & Pleiner (2001) · Acta Scientiarum Naturalium Universitatis Sunyatseni · Cited by 3,419
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
Central nervous system control of food intake and body weight
Morton, G. J., Cummings, D. E., Baskin, D. G., Barsh, G. S., & Schwartz, M. W. (2006) · Nature · doi:10.1038/nature05026 · Cited by 2,503 · cited 2×
“Furthermore, naltrexone and bupropion therapy are believed to influence the mesolimbic dopaminergic reward system,which canmodulate reward behaviors such as food intake (14,15).”
Background
Research works printed but not linked: 1
- Sinnayah, 2007, Bupropion and naltrexone interact synergistically to decrease food intake in mice, Obesity (Silver Spring), 15, A179
Cited by
Items 301–400 of 500
Energy Balance and Weight Loss for Diabetes Remission
Ryan, D. H. (2020) · Diabetes Spectrum · doi:10.2337/ds20-0005 · Cited by 8
Advancements in the management of obesity: a review of current evidence and emerging therapies
Abdalla, M. A., Ssemmondo, E., Mark‐Wagstaff, C., & Sathyapalan, T. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2347258 · Cited by 10
Nguyen, B., & Clements, J. N. (2017) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2017.1367285 · Cited by 12
“The COR-DM study is specific for patients with type 2 diabetes and obesity [40].”
BackgroundInfluentialMishra, S., Gupta, V., Mishra, S., Kulshrestha, H., Kumar, S., Gupta, V., Sachan, R., & Mahdi, A. A. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.07.017 · Cited by 7
Decoding Obesity Management Medications and the Journey to Informed Treatment Choices for Patients
Koball, A. M., Ames, G. E., Grothe, K. B., Clark, M. M., Collazo–Clavell, M. L., & Elli, E. F. (2024) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.10.003 · Cited by 6
Cerchi, E., Santo, P. A. D. E., de Oliveira, M. C., Janovsky, C. C. P. S., & Halpern, B. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01920-4 · Cited by 9
Ruddiman, K. R., Bartfield, J. K., & Hirsch, I. B. (2025) · Obesity · doi:10.1002/oby.70033 · Cited by 10
Differential Efficacy of Weight Loss Interventions in Patients with Versus Without Diabetes
Losada-Díaz, F., Lizarazo-Bocanegra, S., Perdomo-Lugo, J. J., Gutiérrez-Romero, S. A., Correa-Osio, I., & Mendivil, C. O. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01646-y · Cited by 10
Characterization of the effect of naltrexone/bupropion on body composition
Tardio, V., Yin, P., Camacho, F., Barakat, M., & Tsoukas, M. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16235 · Cited by 8
“The weight-reducing properties of NB had been previously established in multiple randomized clinical trials, 13 – 16 and the magnitude of overall weight loss among the subjects in this analysis (7.8% for NB vs. 2.8% with placebo) were consistent with previous findings.”
InfluentialClinical Management of Type 2 Diabetes Mellitus after Bariatric Surgery
Khanna, V., & Kashyap, S. R. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0537-2 · Cited by 7
Current Options for the Pharmacotherapy of Obesity
Gouni‐Berthold, I., & Berthold, H. K. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190708192630 · Cited by 7
Pirlet, C., Poirier, P., Cieza, T., Piché, M., Biertho, L. D., Maes, F., Ruzsa, Z., & Bertrand, O. F. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00428-8 · Cited by 6
Wharton, S., Kamran, E., Thabane, L., Yin, P., & Christensen, R. A. G. (2024) · Clinical Obesity · doi:10.1111/cob.12724 · Cited by 5
A Review of First-Generation Obesity Medications
Schmitz, S. H., & Saunders, K. H. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01389-0 · Cited by 5
“…SR in subjects with obesity or overweight with at least one weight-related comorbidity: Contrave Obesity Research I (COR-I) [ 13], Contrave Obesity Research II (COR-II) [ 23], Contrave Obesity Research Behavioral Modification [ 24], Contrave Obesity Research Diabetes (COR-Diabetes) [ 25].”
Hu, Y., Velu, P., Rohani, P., & Sohouli, M. H. (2023) · European Journal of Clinical Investigation · doi:10.1111/eci.14122 · Cited by 6
Unintended positive and negative effects of drugs on lipoproteins
Siahmansur, T. J., Schofield, J. D., Azmi, S., Liu, Y., Durrington, P. N., & Soran, H. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000198 · Cited by 8
Martínez, J. J. G. (2016) · Medicina Clínica · doi:10.1016/s0025-7753(17)30619-x · Cited by 8
Pharmacotherapy for Weight Management
Brett, E. M. (2018) · Springer eBooks · doi:10.1007/978-3-319-95655-8_21 · Cited by 6
How cardiologists can manage excess body weight and related cardiovascular risk. An expert opinion
Volpe, M., Borghi, C., Cameli, M., Cianflone, D., Cittadini, A., Maggioni, A. P., Filardi, P. P., Rosano, G. M. C., Senni, M., & Sinagra, G. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.03.054 · Cited by 7
Pharmacotherapy for the management of overweight and obesity?
Forner, P. M., & HOCKING, S. L. (2025) · Australian Journal of General Practice · doi:10.31128/ajgp-09-24-7411 · Cited by 8
Lifestyle Therapy for Diabetes Mellitus
Garvey, W. T., & Arathuzik, G. (2016) · Springer eBooks · doi:10.1007/978-3-319-24687-1_22 · Cited by 8
Recent Advances in Anti-Obesity Drugs
Son, J. W. (2022) · Journal of Korean Diabetes · doi:10.4093/jkd.2022.23.2.113 · Cited by 5
“56주 동안 수행된 COR-I 연구에서 Contrave® 최대 용량 을 투여한 환자군은 대조군의 체중감소 1.3% 대비 평균 체 중이 6.1% 유의하게 감소했으며, 5% 이상 체중이 감소한 비 율 역시 대조군 16%와 비교하여 48%로 유의하게 높게 나타 났다[25].”
InfluentialAdipositas und Typ-2-Diabetes (Update 2023)
Clodi, M., Toplak, H., Resl, M., Brix, J. M., Leitner, D. R., Harreiter, J., Hoppichler, F., Wascher, T. C., Schindler, K., & Ludvik, B. H. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-023-02184-6 · Cited by 7
“tes nicht nur hinsichtlich ihrer Gewichtsreduktion zu unterstützen, sondern gleichzeitig auch ihren HbA1cWert zu verbessern [44, 45].”
BackgroundThe Role of Anti-obesity Drugs in Patients with Type 2 Diabetes
Hollander, P. A. (2013) · US Endocrinology · doi:10.17925/use.2013.09.02.101 · Cited by 6
Self-citationPasado, presente y futuro de la farmacoterapia para la obesidad
Benaiges, D., Pedro‐Botet, J., Roux, J. A. F., Climent, E., & Goday, A. (2017) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2017.06.002 · Cited by 9
Onakpoya, I., Collins, D. R. J., Bobrovitz, N., Aronson, J. K., & Heneghan, C. J. (2018) · Obesity · doi:10.1002/oby.22118 · Cited by 7
Lee, C. J., Kim, M.-J., & An, S. J. (2019) · Daehan imsang geon-gang jeungjin hakoeji/Daehan imsang geon'gang jeungjin haghoeji · doi:10.15384/kjhp.2019.19.4.171 · Cited by 5
Sustained-release Naltrexone/Bupropion—A Novel Pharmacologic Approach to Obesity and Food Craving
Fujioka, K. (2015) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2015.11.02.106 · Cited by 6
“Sources: Greenway et al. 2010,58 Wadden et al. 2011,59 Apovian et al. 2013,60 and Hollander et al. 2013.61 Figure 4: Effect of Sustained-release Naltrexone/Bupropion on Eating Behavior -15 -10 -5 0 5 Less More NB Placebo *p<0.05 versus placebo **p<0.01 versus placebo ***p<0.001 versus placebo r…”
BackgroundInfluentialSelf-citationPast, present and future of pharmacotherapy for obesity
Benaiges, D., Pedro‐Botet, J., Roux, J. A. F., Climent, E., & Goday, A. (2017) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2017.06.003 · Cited by 7
Pharmacologic Agents Chapter for Abdominal Obesity
Nuffer, W. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816093-0.00005-7 · Cited by 8
Brooks, B. M., Nettles, A. M., & Brooks, B. M. (2025) · Psychoactives · doi:10.3390/psychoactives4020013 · Cited by 4
Rahman, H. A. U., Fahim, M. A. A., Naeem, U., Ahmed, S. H., Jawad, M. Y., Arshad, H., Kalyoncu, A., Shad, M. U., & Hameed, A. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06873-0 · Cited by 5
“Apovian et al. 2013 and Hollander et al. 2013 also reported significant reductions in NB groups versus placebo (Apo-vian et al. 2013, Hollander et al. 2013 ).”
InfluentialAnker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101445 · Cited by 12
“The Contrave Obesity Research program encompasses a series of four RCTs (COR-I, [117] COR-II, [118] COR-DM [119] and COR-BMOD [120]) that form the central body of literature depicting the efficacy of the naltrexone/ bupropion combination drug in obesity management.”
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.70167 · Cited by 5
“…naltrex-one and 360 mg bupropion [116] The Contrave Obesity Research program encompasses a series of four RCTs (COR-I [117], COR-II [118], COR-DM [119] and COR-BMOD [120]) that form the central body of literature depicting the efficacy of the naltrexone/bupro-pion combination drug in obesity…”
Beyond weight loss: multisystem benefits of obesity medications
Savas, M., Kuckuck, S., Boon, M. R., & van Rossum, E. F. C. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00100-2 · Cited by 5
The Perioperative Implications of New Weight Loss Drugs
Darnobid, J. A., & Jones, S. B. (2016) · Advances in Anesthesia · doi:10.1016/j.aan.2016.07.001 · Cited by 4
Lazarus, E. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100170 · Cited by 8
“Importantly, patients should also be coun-seled on and monitored for signs of neuropsychiatric AEs, such as changes in mood, anxiety, and suicidal ideation, which have occurred in some patients taking bupropion for smoking cessation [33].”
InfluentialNatural Compounds Exert Anti‐Obesity Effects by Regulating Cytokines
Zhang, Y., Feng, G., Zhang, W., & Liu, X. (2025) · Phytotherapy Research · doi:10.1002/ptr.8508 · Cited by 5
Obesity Context of Type 2 Diabetes and Medication Perspectives
Pandit, A., & Pandey, A. K. (2015) · Apollo Medicine · doi:10.1016/j.apme.2015.08.001 · Cited by 4
“38 In a large study, obese type-2 diabetics on oral antidiabetic therapy were bene fi ted by signi fi cant loss of body weight and improved HbA1c pro fi le consequent to administration of naltrexon SR/bupropion SR regime.”
Naltrexon/Bupropion in der Adipositastherapie
Blüher, M. (2018) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/s-0038-1654051 · Cited by 5
Leveraging Population‐Based Clinical Quantitative Phenotyping for Drug Repositioning
Brown, A. S., Rasooly, D., & Patel, C. J. (2017) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12258 · Cited by 6
Lifestyle and Pharmacotherapy for Weight Loss in Preventing or Delaying Diabetes
Price, S. A., Le, Q. N., & White, N. D. (2017) · American Journal of Lifestyle Medicine · doi:10.1177/1559827617740825 · Cited by 5
Rationale for Utilization of Obesity Pharmacotherapy in the Active Duty Population*
Nadolsky, K. Z. (2018) · Military Medicine · doi:10.1093/milmed/usx074 · Cited by 4
Model‐Based Approach to Predict Adherence to Protocol During Antiobesity Trials
Sharma, V. D., Combes, F. P., Vakilynejad, M., Lahu, G., Lesko, L. J., & Trame, M. N. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.994 · Cited by 6
(2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2026-006247 · Cited by 11
Saidi, A. N., Konings, L. A. M., Dietvorst, C. A. W., de Jong, V., Brouwer, W. P., van der Lelij, A., Alings, M., van Wenum, M., Rauh, S. P., Xu, W., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70071 · Cited by 6
“11 In comparison with existing literature, studies investigating GLP-1 receptor agonists such as semaglutide and liraglutide similarly emphasize the central role of weight loss in improving liver outcomes in MASLD.”
InfluentialAhmed, I. S., Tapponi, S. L., Manaa, H. M., Soltani, A., Hussein, E. S., Parvaresh, F. A., & Hussain, Z. (2026) · Journal of Obesity · doi:10.1155/jobe/6556057 · Cited by 5
Pharmacologic Treatment of Obesity in the Context of Type 2 Diabetes
Conte, C., & Amaro, A. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01626-5 · Cited by 3
Gudzune, K. A., Perreault, L., Apovian, C. M., Aroda, V. R., Aronne, L. J., Fitch, A., Fitzpatrick, S. L., Garvey, W. T., Kahan, S. I., Khunti, K., et al. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doci26-0003 · Cited by 13
Medical Weight Management: A Multidisciplinary Approach
Elhag, W., & Ansari, W. E. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.105475 · Cited by 3
Pharmacological treatment of obesity
Anglart, G., Dominiak, K., & Dettlaff, K. (2023) · Farmacja Polska · doi:10.32383/farmpol/161473 · Cited by 5
Carmo‐Silva, S., & Nóbrega, C. (2024) · Springer eBooks · doi:10.1007/978-3-031-62491-9_2 · Cited by 3
First-Generation Anti-Obesity Medications
Barenbaum, S. R., & Aras, M. (2024) · Diabetes Spectrum · doi:10.2337/dsi24-0003 · Cited by 5
Consenso ALAD. Tratamiento del paciente con diabetes mellitus tipo 2 y obesidad
BRAJKOVICH, I. E., Aschner, P. J., Taboada, L. B., Camperos, P., Gómez‐Pérez, R., Aure, G., Velásquez, M. E., Halpern, B., Jiménez, M. C. H., & Fuentes, O. (2019) · Alad · doi:10.24875/alad.19000369 · Cited by 11
A contemporary view on obesity treatment in adults
Velychko, V. I., Mankovsky, B., Татарчук, Т. Ф., Lahoda, D. O., Todurov, I. M., & Ліщишина, О. М. (2021) · Reproductive Endocrinology · doi:10.18370/2309-4117.2021.61.45-50 · Cited by 6
Obesity Pharmacotherapy: a Review of Current Practices and Future Directions
Schmitz, S. H., Tchang, B. G., & Shukla, A. P. (2023) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-023-00409-1 · Cited by 5
“Similar weight loss was reported in the COR-II and COR-Diabetes trials [23, 24].”
ResultJiang, Q., Velu, P., Sohouli, M. H., Ziamanesh, F., Shojaie, S., Fatahi, S., & Li, Q. (2023) · European Journal of Clinical Investigation · doi:10.1111/eci.14118 · Cited by 3
Patel, Y. S., & Malvestutto, C. (2024) · Journal of AIDS and HIV Treatment · doi:10.33696/aids.6.047 · Cited by 5
Control of Eating Attributes and Weight Loss Outcomes over One Year After Sleeve Gastrectomy
Lytvyak, E., Zarrinpar, A., Ore, C. L. D., Lee, E., Yazdani-Boset, K., Horgan, S., & Grunvald, E. L. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07158-9 · Cited by 5
A Saudi Heart Association Position Statement on Obesity and Cardiovascular Disease
AlHabeeb, W., Kinsara, A. J., Bakhsh, A., Tash, A. A., Alshammary, A., Almasood, A. S., Alghalayini, K. W., Arafah, M., Hamdy, O., Alsifri, S. N., et al. (2024) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1391 · Cited by 6
Lyu, Y. S., Ahn, H. Y., Hong, S., & Park, C. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s492913 · Cited by 7
“10 11–13 Despite the promising outcomes observed in randomized controlled trials (RCTs) and meta-analysis, 9,11–14 post-marketing surveillance is imperative for assessing the real-world effectiveness and safety profile of naltrexone-bupropion therapy.”
InfluentialCombined medical strategies for the management of type 2 diabetes mellitus and obesity in adults
Tarazi, M. S., Touhamy, S., Tchang, B. G., & Shukla, A. P. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1942841 · Cited by 4
Krentz, A. J., & Rodriguez‐Araujo, G. (2017) · Pharmaceutical Medicine · doi:10.1007/s40290-017-0209-3 · Cited by 3
“Improvements in glycaemic control and selected cardiovascular risk factors have been demonstrated with naltrexone/bupropion in patients with type 2 diabetes [138].”
Obesity Treatment: A Focus on Pharmacotherapy of Weight Management
Patel, K. (2020) · Orthopaedic Nursing · doi:10.1097/nor.0000000000000643 · Cited by 5
Pharmacotherapy in obesity: the current state and the near future
Cho, Y. J., & Kim, K. K. (2022) · Journal of Korean Medical Association · doi:10.5124/jkma.2022.65.8.514 · Cited by 3
HIV Treatment and Obesity: What’s New?
Freitas, P., & Ribeiro, S. (2023) · Infectious diseases · doi:10.5772/intechopen.112667 · Cited by 2
Terapia farmacologica dell’obesità: attualità e prospettive future
Vinciguerra, F., & Frittitta, L. (2022) · L Endocrinologo · doi:10.1007/s40619-022-01068-7 · Cited by 2
An Overview of Modern Strategies for Treating Obesity
Jędrasek, A., Barg, M., Biały-Karbowniczek, J., Bartela, A., & Wojtyła, K. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.68.49506 · Cited by 2
TERAPIAS FARMACOLÓGICAS PARA TRATAR OBESIDADE: ANÁLISE DE EFEITO E EFICÁCIA
Freitas, T. M., Mota, F. L. D. O., & Pinheiro, A. P. (2024) · Revista Foco · doi:10.54751/revistafoco.v17n10-082 · Cited by 7
Fang, Y., Yeh, Y., Liu, T., Tien-Wei, H., & Ko, C. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106108 · Cited by 4
Yskout, M., Steenackers, N., Hoste, J., Pazmiño, S., Simoens, C., Mattelaer, N., Deleus, E., Lannoo, M., Mertens, A. C., der Schueren, B. V., et al. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01870-x · Cited by 4
“This cohort resembles well the clinical trial population for weight management using GLP-1 analogues and NB [12, 16, 17, 25 – 27].”
Howland, R. H. (2015) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20150526-02 · Cited by 5
Wyleżoł, M., & Olszanecka‐Glinianowicz, M. (2017) · Nutrition Obesity & Metabolic Surgery · doi:10.5114/noms.2017.69832 · Cited by 4
“Clinical studies have demonstrated the hyper-additional (potentiating) effect of the combination of bupropion hydrochloride and naltrexone hydrochloride on weight loss [27-30].”
BackgroundCentral Nervous System Stimulants and Drugs That Suppress Appetite
Bello, N. T. (2015) · Side effects of drugs annual · doi:10.1016/bs.seda.2015.08.004 · Cited by 3
Naltrexone ER/bupropion ER in obesity management: a guide to its use
Greig, S. L., & Keating, G. M. (2015) · Drugs & Therapy Perspectives · doi:10.1007/s40267-015-0253-6 · Cited by 2
“In addition to receiving naltrexone ER/ bupropion ER or placebo, the patients were instructed to increase physical activity [8–11] and follow a hypocaloric diet (500 kcal/day deficit) [8, 9, 11].”
BackgroundMethodResultInfluentialPharmacological Management of Obesity in Patients with Type 2 Diabetes: An Update
Lee, E. J., & Kim, T. N. (2016) · The Korean Journal of Obesity · doi:10.7570/kjo.2016.25.3.121 · Cited by 2
“8% with placebo and weight loss was maintained for the 56-week period, with no evidence of weight regain.(53) This weight loss was associated with improvements in glycemic control (A1C: placebo-corrected difference -0.”
BackgroundPalmer, K. D., & Apovian, C. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802928-2.00022-9 · Cited by 2
Management of Obesity in Patients with Diabetes Mellitus
Lee, M. J., & Kim, S. S. (2017) · Journal of Korean Diabetes · doi:10.4093/jkd.2017.18.4.229 · Cited by 2
Klein, P., Tyrlíková, I., Pirolli, N. H., Barber, A., Tyrlík, M., & Goldman, L. (2019) · Journal of Obesity and Chronic Diseases · doi:10.17756/jocd.2019-024 · Cited by 3
“Treatment with the 5 FDA-approved long-term weight loss agents, orlistat, qysimia, lorcaserin, contrave and liraglutide achieve both weight loss and improvement in glycemic control in overweight/obese T2D patients, but the results are modest [17-23] Virtually no T2DM remissions are reported.”
BackgroundHistopathological Effects of Carbamazepine on The Reproductive System of Male Rats
Majeed, H. A. (2021) · Al-Qadisiyah Journal Of Pure Science · doi:10.29350/qjps.2021.26.2.1297 · Cited by 2
Mitochondrial dysfunction in metabolic disorders
Advani, D., Sharma, S., Tripathi, R. S., Gupta, R. V., Jaiswal, A., Ambasta, R. K., & Kumar, P. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85666-9.00015-2 · Cited by 4
von Heesen, M. (2022) · Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie · doi:10.1055/a-1970-3664 · Cited by 2
“[47] Hollander P, Gupta AK, Plodkowski R et al.”
BackgroundPharmacotherapy of Obesity and Metabolic Syndrome
Duan, D., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_44 · Cited by 4
Pharmacological treatment of obesity
Ferreira‐Hermosillo, A., Salame, L., & Abruch, D. C. (2018) · PubMed · Cited by 10
Therapeutic Management of Obesity
Bray, G. A. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_17 · Cited by 4
Matta-Coelho, C., Agius, R., Crane, J. D., & McGowan, B. M. (2021) · British Journal of Diabetes · doi:10.15277/bjd.2021.281 · Cited by 2
Danda, V. R., Bailey, C. R., & Weiss, C. R. (2020) · Digestive Disease Interventions · doi:10.1055/s-0040-1712084 · Cited by 1
Shea, M. K., Lynch, S. D., Brinkley, T. E., & Kritchevsky, S. B. (2025) · Current Developments in Nutrition · doi:10.1016/j.cdnut.2025.107485 · Cited by 2
Cardiometabolic risk effects of weight‐loss medications: An updated network meta‐analysis
Wang, D., Diao, H., Sun, W., Huan, W., Wang, Y., Ding, L., Cui, W., & Ma, K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16585 · Cited by 3
A New Era in the Medical Management of Obesity
Porterfield, F., Fatima, A., Boaventura, B. C. B., Madhar, A., Srivastava, G., & Stanford, F. C. (2026) · Annual Review of Medicine · doi:10.1146/annurev-med-043024-125437 · Cited by 3
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1445 · Cited by 1
Kyle, M., Savastano, D. M., Sharpe, T. A., & Kelly, B. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100280 · Cited by 1
Xie, J., Yang, Y., Chen, W., (45927), L. W., Weng, S., Lyu, Q., & Cao, G. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00722-7 · Cited by 1
Medikamentöse Behandlung der Adipositas
Engeli, S. (2016) · PSYCH up2date · doi:10.1055/s-0041-106154 · Cited by 1
Beyond Traditional Management: The Use of Medications in the Treatment of Obesity
Blackstone, R. P. (2016) · Springer eBooks · doi:10.1007/978-3-319-39409-1_10 · Cited by 1
Nutrition Therapy for the Prevention and Treatment of Prediabetes and Diabetes
Franz, M. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-43027-0_8 · Cited by 1
Hatékony és biztonságos terápia az elhízás gyógyszeres kezelésében: a naltrexon/bupropion kombináció
Hídvégi, T. (2017) · Diabetologia Hungarica · doi:10.24121/dh.2017.32 · Cited by 1
Metabolic disorders: Sex and gender evidence in dyslipidemia, diabetes, and obesity
Newman, C. B., Saunders, K. H., & Subramanian, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816569-0.00009-7 · Cited by 1
Abnehmen mit Arzneimitteln? Pharmakotherapie von Übergewicht und Adipositas
Smollich, M. (2021) · Aktuelle Ernährungsmedizin · doi:10.1055/a-1118-2562 · Cited by 1
Obesity: Medical and Surgical Treatment
Tassinari, D., Giovanelli, A., & Asteria, C. (2021) · Springer eBooks · doi:10.1007/978-3-030-80267-7_9 · Cited by 1
Metadata
- Authors
- Hollander, P., Gupta, A. K., Plodkowski, R., Greenway, F., Bays, H., Burns, C., Klassen, P., Fujioka, K., & for the COR-Diabetes Study Group
- Affiliations
- Baylor University Medical Center (US)
- Pennington Biomedical Research Center (US)
- Scripps Clinic (US)
- Louisville Metabolic and Atherosclerosis Research Center (US)
- Orexigen Therapeutics (United States) (US)
- Corresponding author
- Hollander, Priscilla
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-11-13
- Volume
- 36
- Issue
- 12
- Pages
- 4022-4029
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3836105
- OpenAlex
- W2020982355
- Cited by
- 501
- References
- 39
- Citations by year
- 2026: 29 · 2025: 50 · 2024: 56 · 2023: 51 · 2022: 35 · 2021: 47 · 2020: 34 · 2019: 27 · 2018: 34 · 2017: 40 · 2016: 42 · 2015: 43 · 2014: 12 · 2013: 1
- FWCI
- 23.98
- Type
- journal article
- Language
- en
- Update notices
- correction (2014-02-01)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- naltrexone/bupropion, combination therapy, type 2 diabetes, obesity, overweight, weight loss, glycemic control, HbA1c, triglycerides, HDL cholesterol, nausea, constipation, vomiting, antidepressant side effects, cardiovascular risk factors, lifestyle intervention, drug safety, drug efficacy, suicidal ideation, hypoglycemia
- MeSH terms
- Adolescent, Adult, Aged, Blood Glucose, Body Weight, Delayed-Action Preparations, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Naltrexone, Narcotic Antagonists, Obesity, Retrospective Studies, Risk Factors, Weight Loss, Bupropion, Treatment Outcome, Antidepressive Agents, Second-Generation, Overweight, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.